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This article presents local protocols for antithrombotic therapy used in a tertiary care
institution—the cardiocenter of a university hospital. The protocols were discussed in
detail among the whole team of physicians of the cardiocenter. This article addresses
cardiac conditions requiring hospitalization whenever antithrombotic therapy is indicated.
These protocols do not include antithrombotic therapy in other medicinal disciplines (e.g.,
orthopedics, surgery). These protocols are mostly based on the current guidelines of the
European Society of Cardiology (ESC). The partial differences between the ESC guidelines
and this text are usually based on the results of the latest clinical trials, which have not yet
been included in the ESC guidelines.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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c o r e t v a s a 5 5 ( 2 0 1 3 ) e 2 0 1 – e 2 0 6e202are usually based on results of the latest clinical trials, which
have not yet been included in the ESC or CKS guidelines.
Several modern and effective drugs included in these
protocols are not yet fully covered by the Czech health
insurance system, and patients need to pay part of their
price (sometimes a significant amount). While prescribing
these drugs, physicians are obliged to inform patients about
differences in the effectiveness and safety in comparison
with cheaper alternative drugs and also the amount the
patient would be required to pay. The final decision whether
to prescribe the cheaper or the more expensive drug must be
based on the patient’s wishes.2. Positive list of used drugs (Table 1)
Maximal balance payment for outpatient prescribed drugs
(status during 2012) (Table 2):
(Maximal balance payment for the patient according to the
Czech Ministry of Health as of December 28, 2012; for details
see www.mzcr.cz/leky.aspx)
1. Large myocardial infarction with an indication for urgent
(right after admission) coronary angiography: acute ST eleva-
tion myocardial infarction (STEMI) or myocardial infarction
with deep ST depressions (STDMI) or myocardial infarction
with new-onset bundle branch block (RBBB-MI, LBBB-MI) orTable 1 – Positive list of used drugs.























Table 2 – Maximal balance payment for outpatient prescribed
Drug Price (CZK) Insuran
reimbu
Trombex 75 mg (30 tbl) 493, – 493, –
Efient 10 mg (28tbl) 1520, – 384, –
Efient 5 mg (28 tbl)
Brilique 90 mg (56 tbl) 2123, – 383, –
Warfarin 3 mg (100 tbl) 154, – 155, –
Warfarin 5 mg (100 tbl) 235, – 191, –
Pradaxa 110 mg (60 cps) 2200, – 2100, –
Pradaxa 150 mg (60 cps) 2200, – 2100, –
Xarelto 15 mg (28 tbl) 2242, – 1416, –
Xarelto 20 mg (28 tbl) 2242, – 1888, –myocardial infarction causing cardiogenic shock or malig-
nant arrhythmias [1,2].
Right after the diagnosis (in the ambulance, in the non-PCI-
capable hospital, in the emergency admission department,
upon arrival to the cathlab, etc.): Kardegic 0.5 g i.v.þEfient
60 mg p.o.þHeparin 70 IU/kg i.v.
If Efient is contraindicated, Trombex 600mg should be used
instead. In patients premedicated with Trombex, the use of
Brilique 180mg p.o. should be considered instead of Efient.
During urgent coronary angiography/PCI: If any of the three
above-mentioned drugs were not administered before coron-
ary angiography, administer them as soon as possible in the
cathlab. The interventional cardiologist can decide whether
to use an additional dose of heparin (until a total dose of
100 IU/kg) or alternatively whether to administer eptifibatide.
The decision for eptifibatide use should be explained in
documentation.
After primary PCI (regardless of the type of implanted stent):
Anopyrin 100 mg daily indefinitely and Efient 10 mg daily for
up to 12 months (or Brilique 290 mg daily up to 12 months).
In patients with weight o60 kg or age 475 years, an indivi-
dual decision should be made (Trombex 75 mg daily or Efient
5 mg daily).
Clexane 0.4 ml s.c. daily should be considered during bed
rest (last dose when the patient gets up from the bed).
The first dose of Clexane should be administered after
removing the compression over the site of puncture. The
second dose (when the patient is still bed-rested) should be
administered after 24 h.
If the patient refuses to pay for Efient (or Brilique), the
attending physician is obliged to replace, before discharge,
Efient (or Brilique) with Trombex 275 mg daily until day 14
after myocardial infarction, followed by 75 mg daily for up to
12 months.
2. Other forms of acute coronary syndrome (ACS) with
coronary angiography indicated within 24 h after admission:
unstable angina (UA) with negative troponin, troponin-
positive myocardial infarction without ST segment changes
or without new bundle brunch block (trop-IM) [2].
On admission: Anopyrin 400 mg p.o.þClexane at a ther-
apeutic dose (1 mg/kg s.c. twice daily). The decision
whether to use a P2Y12 inhibitor will be made right
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renal failure and GFR 30–60 ml/min/1.73 m2, the dose of
Clexane needs to be reduced (1 mg/kg s.c. once daily).
Administration of Clexane before coronarography is not
interrupted. In patients with GFR o30 ml/min/1.73 m2,
Heparin (UFH) 60 IU/kg i.v. in a bolus dose and then by
continual infusion of 15 IU/kg/h (maximally 1000 IU/h) is
used instead of Clexane.
During coronarography7PCI: If ad hoc PCI is indicated right
after coronarography, Efient 60mg p.o. is administered in the
cathlab. In patients medicated early with Trombex, and/or with a
history of TIA and/or ischemic stroke and/or weighto60 kg and/
or age 475 years, Brilique 180mg p.o. should be used instead.
If ad hoc PCI is not indicated and the patient is stable, the
decision about treatment with P2Y12 inhibitors is made after
exclusion of indication of CABG.
The interventional cardiologist can decide whether to
administer eptifibatide. This decision must be later explained
in documentation.
Patients treated with Clexane who did not receive the
latest dose within 8 h before PCI should be treated with a
bolus dose of Clexane 0.3 mg/kg i.v. before PCI.
After PCI (regardless of the type of implanted stent): Anopyrin
100 mg daily indefinitely. Efient 10 mg daily for up to 12
months (or Brilique 290 mg daily up to 12 months). In
patients with weight o60 kg and/or age 475 (see commen-
tary at the end of the article), give Trombex 75 mg daily or
Efient 5 mg daily. The sheath can be removed 6 h after the
latest i.v./s.c. dose of Clexane. Clexane 0.4 ml s.c. daily should
be considered during bed rest (last dose when the patient gets
up from the bed). The first dose of Clexane should be
administered after removing the compression over the site
of puncture. The second dose should not be administered
earlier than 24 h later.
If the patient refuses to pay for Efient (or Brilique), the
attending physician is obliged to replace, before discharge,
Efient (or Brilique) with Trombex 75 mg daily.
3. PCI with implantation of a drug-eluting stent (DES) in
patients with chronic forms of coronary artery disease
Patients with chronic coronary artery disease are usually
treated with Anopyrin 100 mg daily. This treatment remains
the same before and after PCI.
In cathlab Heparin 25 IU/kg is usually administered before
coronarography (the interventional cardiologist can decide
not to use this treatment if a short duration of coronarogra-
phy is expected, especially in females). In case of ad hoc PCI
after coronarography, an additional dose of Heparin up to a
total dose of 70–100 IU/kg is administered. Other anticoagula-
tion after PCI is not indicated (except when there is a separate
indication).
If PCI is performed ad hoc after coronarography, no specific
preparation of the patient before coronarography is neces-
sary. The patient is treated with Trombex 600 mg p.o. right
after coronarography (before PCI).
If PCI is scheduled (coronarography is already known), the
patient receives 600 mg of Trombex p.o. any time between 24
and 2 hours before PCI.
After PCI Trombex 75 mg daily is indicated for up to 6
months (in individual patients with increased bleeding riskand use of a XIENCEs or RESOLUTEs stent, dual antiplate-
let therapy can extend for up to 3 months). In high-risk
patients (increased risk of stent thrombosis, a single last
patent conduit, PCI of left main or multiple-vessel PCI), the
interventional cardiologist can decide to administer dual
antiplatelet therapy for up to 12 months (possibly even
longer). In these high-risk patients, the platelet response to
clopidogrel should be assessed. If resistance to clopidogrel
is verified, Trombex is switched to Efient 10/5 mg daily (if
there are no contraindications and the patient gives
consent).
4. PCI with implantation of bare-metal stent (BMS) or PCI
without implantation of stent in patients with chronic cor-
onary artery disease
The operating procedure is the same as in previous case
[3], only the period of treatment with Trombex is up to 1
month. Efient is not indicated in this case. If no stent was
implanted, treatment with Trombex is not indicated, and
only Anopyrin 100 mg is administered daily.
5. Chronic forms of coronary artery disease without recently
implanted stent
Anopyrin 100 mg daily is used indefinitely. Patients intol-
erant to aspirin can receive Trombex 75 mg daily.
6. Recently implanted stent (any indication, including ACS) in
combination with any other condition (e.g., atrial fibrillation),
which is an indication for oral anticoagulation (including
patients already treated by anticoagulants)
Radial access is preferred. If INRZ2.0, no periprocedural
treatment with heparin is necessary. The interventional cardiol-
ogist can decide whether to administer eptifibatide.
If there is a known indication for chronic anticoagulation, the
patient should receive a bare-metal stent (not DES). The only
exception (i.e., when DES can be implanted) is the case of PCI for
in-stent restenosis in patients without known bleeding risks.
The bleeding/thromboembolic risk ratio must be assessed.
If any type of stent is implanted and the indication to PCI
is ACS, 6 months of dual therapy with Warfarin
(INR 2.0–2.5)þTrombex 75 mg daily followed by monotherapy
with Warfarin (INR 2.0–3.0) is indicated. If the indication for a
bare-metal stent was chronic coronary artery disease, dual
therapy of WarfarinþTrombex is indicated for up to 1 month,
followed by monotherapy with Warfarin [4].
In patients taking chronic oral anticoagulation with a DES
implant, the management of antiplatelet therapy is the same as
in an ACS (6 months dual therapy with TrombexþWarfarin,
followed by monotherapy with Warfarin).
Cave: In patients treated with combination Warfarinþ
antiplatelet drug, prevention of gastrointestinal bleeding using
proton pump inhibitors is important. Omeprazole is less appro-
priate. Lansoprazole (Lanzul) or pantoprazole (Nolpaza) is recom-
mended; both drugs are approved in the Czech Republic.
7. Chronic coronary artery disease without recently implanted
stent or other condition requiring oral anticoagulation
Warfarin, target INR 2.0–3.0. Anopyrin is not required.
8. Atrial fibrillation (AF) [3]
Thromboembolic risk (CHA2DS2-VASc—see http://www.
mdcalc.com/cha2ds2-vasc-score-for-atrial-fibrillation-stro
Table 4 – Absolute contraindications of thrombolysis in
massive pulmonary embolism.
Prior history of hemorrhagic stroke or stroke of unknown
etiology
History of ischemic stroke in previous 6 months
CNS damage or neoplasia
Large surgery/injury/cranial injury in previous 3 weeks
History of gastrointestinal bleeding in previous month
Known bleeding
Table 3 – Long-term oral anticoagulation based on scor-
ing systems for thromboembolic and bleeding risk
calculation.




CHA2DS2-VASc–1 Pradaxa or Xarelto
or Warfarin
Anopyrin
CHA2DS2-VASc Z2 Pradaxa or Xarelto
or Warfarin
Individual decision
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mdcalc.com/has-bled-score-for-major-bleeding-risk/) should
be assessed in every patient with atrial fibrillation. Decisions
about long-term oral anticoagulation are based on these
scoring systems—(see Table 3):
The patient needs to be informed about all issues
(Warfarin vs. new anticoagulants), including practical aspects
(INR, prices of drugs). The final decision of the patient has to be
respected.
Dosing: Warfarin with target INR 2.5–3.5 (valve prosthesis
in mitral position, recent pulmonary embolism and other
high-risk conditions) or target INR 2.0–3.0 (most of the
conditions when therapy with Warfarin is indicated) or target
INR 2.0–2.5 (combination of Warfarin with an antiplatelet
drug, low-risk atrial fibrillation, prior history of bleeding).
Pradaxa 150 mg twice daily (most of the patients with atrial
fibrillation indicated for treatment with Pradaxa) or 110 mg
twice daily (patients with higher bleeding risk, age over 80
years, use of verapamil, HAS-BLED score Z3, creatinine
clearance 30–49 ml/min). Xarelto 20 mg once daily or 15 mg
once daily in higher-bleeding-risk patients (HAS-BLED score
Z3 and/or creatinine clearance 30–49 ml/min). Pradaxa and
Xarelto are not recommended in patients with creatinine
clearance o30 ml/min.
9. Acute pulmonary embolism
Thrombolysis administered in one dose t-PA 100 mg i.v. for
30–120 min is indicated in massive pulmonary embolism
(severe dyspnea with hemodynamic instability, right ventricle
larger than left ventricle by echocardiography). The speed of
infusion is regulated by the clinical condition of the patient:
patients in most critical conditions require a faster infusion.
This form of one-dose thrombolysis needs to be considered
also in situations when primary anticoagulation treatment
with heparin (UFH/Clexane) does not lead to remission of
dyspnea, tachycardia, and hypoxemia and to normalization
of right ventricle size. Prolonged thrombolysis: Streptokinase
500,000 IU bolus doseþsubsequent infusion at 100,000 IU/h
for 12–72 h should be considered in patients with unambigu-
ously diagnosed (CT or pulmonary angiography) subacute
(estimated time of duration: a few weeks) and very large
pulmonary embolism (persisting dilatation of right ventricle).
Parenteral anticoagulation: Heparin or Clexane is indicated
either after thrombolysis in case of massive pulmonary
embolism or as a primary treatment in other forms of
pulmonary embolism. The duration of parenteral treatment
depends on the clinical condition of the patient: switching to
Warfarin can be started after remission of all symptoms(complete relief from dyspnea), full hemodynamic stabiliza-
tion and normalization of right ventricle size (in cases where
the right ventricle was not dilated before the recent episode
of pulmonary embolism). Dosage of Clexane: 1 mg/kg s.c.
twice daily (12 h). Dosage of heparin: bolus dose 80 IU/kg
(bolus dose is not administered after thrombolysis), followed
by infusion of 18 IU/kg/h, with the dose titration speed
according to APTT (target values 65–85 s).
Peroral anticoagulation is initiated after complete stabiliza-
tion of the patient and normalization of echocardiography
findings. If Warfarin is used, its initial dose is 10 mg daily,
followed by 5mg daily. Daily control of INR should be per-
formed. As soon as INR reaches 2.5, Heparin or Clexane is
discontinued. Patients with a primary history of pulmonary
embolism are treated with Warfarin for up to 6 months (in
patients with high bleeding risk, 3 months is satisfactory) with
target INR 2.0–3.0. If the patient has a history of pulmonary
embolism, or the patient has a thrombophilic condition and
high risk of thromboembolic events and does not have a high
bleeding risk, Warfarin should be administered indefinitely.
After discontinuation of Warfarin, treatment with Anopyrin
should be considered for the next 3–6 months.
10. Deep vein thrombosis without pulmonary embolism
Initial treatment is done with UFH 80 IU/kg i.v. bolus
dose followed by continuous infusion of UFH 18 IU/kg/h
(target aPTT 60–80 s), or Clexane 1 mg/kg s.c. every 12 h.
Treatment with Warfarin can be started 1 or 2 days after
initiation of parenteral anticoagulation. Principles of per-
oral anticoagulation are the same as in the case of
pulmonary embolism. If Xarelto is used, the initial dose
for the treatment of deep vein thrombosis is 15 mg
2daily for the first 3 weeks, followed by 20 mg once
daily. The duration of anticoagulation therapy in deep vein
thrombosis is based on the same principles as in pulmon-
ary embolism. After discontinuation of treatment with
Warfarin, treatment with Anopyrin should be considered
for the next 3–6 months (Table 4).
11. Stroke (including TIA)
Treatment of stroke is managed by the neurologist. In case of
hemorrhagic stroke, it is managed in cooperation with the
neurosurgeon. Severe or moderate acute ischemic stroke (NIHSS
Z8) is treated depending on CT findings and the time interval
between the onset of stroke and execution of CT. Ischemic
strokes lasting less than 3 h are treated by catheterization
intervention (thrombectomy or angioplasty), or in the case of
immediate inaccessibility of catheterization (less than 30min
from CT), strokes are treated by thrombolysis (0.9 mg/kg rt-PA in
an infusion lasting 60min). Upon appropriate CT findings
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performed up to 6 h after the start of the stroke. In severe strokes
affecting the catchment area of the vertebral artery or the basilar
artery, intervention can be considered up to 8 h after the start of
the symptoms. In the case that stroke occurs during cardiac or
other vessel catheterization as an unexpected complication of
the procedure, immediate angiography is indicated (with no
previous CT examination), and if thromboembolic obstruction
is confirmed, urgent intervention for the obstruction follows.
Mild strokes (NIHSS o8) are usually treated conservatively—
always after consultation with the neurologist. Secondary
prevention after stroke is individual and depends on CT
findings and on the probable etiology of the ischemic stroke
(cardioembolization vs. arterial thrombosis). Anopyrin, Aggre-
nox, Trombex and Warfarin (alternatively Xarelto or Pradaxa)
are the drugs of choice. The particular therapy and dosage is
always indicated by the neurologist.
12. Coronary artery bypass graft surgery with no further
indication for anticoagulation therapy
Administration of acetylsalicylic acid (100mg daily) can be
initiated 12–24 h after a surgery and should continue indefinitely.
Patients intolerant to ASA can receive Trombex 75mg daily. In a
case the indication for CABG was acute coronary syndrome, dual
antiplatelet therapy (acetylsalicylic acid 100mg/day and Trom-
bex 75mg/day) is indicated for up to 12 months.
13. Coronary artery bypass graft surgery with indication for
anticoagulation therapy
Clexane s.c. should be administered starting 1 day after
surgery at a maximal dose of 0.5mg/kg 2daily (e.g., 60 kg¼
20.3ml). Starting 2 days after surgery, Warfarin is added (men
5mg/day, women 3mg/day). When Warfarin is at an effective
level (INR42.0) Clexane is discontinued. Simultaneous treatment
with acetylsalicylic acid 100mg/day can be considered.
14. Discontinuation of antiplatelet or anticoagulation therapy
before coronary artery bypass graft surgery
Elective indication (code C): All antithrombotic drugs
(Warfarin, clopidogrel, acetylsalicylic acid) are discontin-
ued 7 days before surgery. Indication during the same
hospitalization as coronary angiography (code B): Warfarin
and clopidogrel are discontinued at the moment of indica-
tion for surgery; acetylsalicylic acid is discontinued if the
patient is free of chest pain for more than 3 days. Urgent
indication (code A): Warfarin and clopidogrel are discon-
tinued at the moment of indication; treatment with acet-
ylsalicylic acid can continue until surgery. In patients with
an effective level of antiaggregation therapy, administra-
tion of tranexamic acid (and thrombocyte concentrate) is
indicated before surgery. If the indication for operation is
acute coronary syndrome, treatment with Heparin or
Clexane continues until surgery. Importantly, Heparin
cannot be discontinued in unstable patients—there is a
risk of rebound phenomenon and myocardial infarction
right before surgery.
15. Aortic valvuloplasty or aortic valve replacement using
bioprosthesis
Patients with no risk factors (atrial fibrillation, history of
thromboembolic event, left ventricle dysfunction, thrombophilia)
are treated only with antiplatelet therapy: acetylsalicylic acid(100mg daily). In case of the presence of risk factor(s), Clexaneþ
Warfarin are indicated [5].
16. Mitral valvuloplasty or mitral valve replacement using
bioprosthesis
Anticoagulation therapy using Warfarin up to 3 months
with target INR 2.0–3.0 is indicated [5].
17. Valve replacement using metallic valve prosthesis
Clexane s.c. is administered starting 1 day after surgery with
a maximal dose of 0.5mg/kg 2daily (e.g., 60 kg¼20.3ml).
Starting 2 days after surgery, Warfarin is added (men 5mg/day,
women 3mg/day). When Warfarin is at an effective level
(INR42.5), Clexane is discontinued. Target values of INR are
2.5–3.5 [5].
18. TAVI
ASA 100–200 mg/day indefinitely and Trombex 75 mg/day
up to 6 months after the procedure. Trombex 300 mg loading
dose 1 day before the procedure.3. Notes on the new antithrombotics
Prasugrel (Efient) is contraindicated in patients with prior
history of stroke or TIA and in patients with severe hepatic
damage (Child-Pugh). Prasugrel is not recommended in
patientsZ75 years old. The dose of Efient in the maintenance
phase of treatment in patients with weighto60 kg is reduced
to 5 mg daily. The recommended time of discontinuation of
Efient before elective surgery is 7 days.
Ticagrelor (Brilique) is contraindicated in patients with prior
history of intracranial bleeding and in patients with moderate
and severe hepatic damage. The recommended time of
discontinuation of Brilique before elective surgery is 7 days.
Dabigatran (Pradaxa) is not recommended in patients with
severe renal failure (CrCL o30 ml/min). Patients with eleva-
tion of liver enzymes to more than twice the upper limit of
normal have been excluded from clinical trials investigating
the prevention of stroke and systemic embolization in
patients with atrial fibrillation. This lack of experience with
treatment of this subpopulation is a reason why Pradaxa is
not recommended in this case.
Rivaroxaban (Xarelto) is not recommended in patients with
severe renal failure (CrCL o30 ml/min). This drug is contra-
indicated in patients with liver disease connected with
coagulopathy and clinically relevant bleeding, including
patients with liver cirrhosis (Child-Pugh B and C).
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